Scarica l'app Stockscreener
17.92
10.29%
1.69
Dopo l'orario di chiusura:
17.92
Precedente Chiudi:
$16.23
Aprire:
$17.39
Volume 24 ore:
9.32M
Relative Volume:
4.44
Capitalizzazione di mercato:
$1.87B
Reddito:
-
Utile/perdita netta:
$-238.77M
Rapporto P/E:
-0.6685
EPS:
-26.808
Flusso di cassa netto:
$-216.62M
1 W Prestazione:
+83.40%
1M Prestazione:
+60.97%
6M Prestazione:
+440.79%
1 anno Prestazione:
+122.36%
Intervallo 1D:
$16.70
$18.57
Intervallo di 1 settimana:
$7.85
$22.30
Portata 52W:
$2.7601
$22.30
Alumis Inc Stock (ALMS) Company Profile
Nome
Alumis Inc
Settore
Industria
Telefono
650-231-6625
Indirizzo
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Confronta ALMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
17.92 | 1.69B | 0 | -238.77M | -216.62M | -26.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Ripresa | Guggenheim | Buy |
| 2025-01-30 | Iniziato | Oppenheimer | Outperform |
| 2024-10-31 | Iniziato | Robert W. Baird | Outperform |
| 2024-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Iniziato | Guggenheim | Buy |
| 2024-07-23 | Iniziato | Leerink Partners | Outperform |
| 2024-07-23 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Alumis Inc Borsa (ALMS) Ultime notizie
Should You Chase the Rally in Alumis Stock Today? - Barchart.com
Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise (ALMS) - Seeking Alpha
Biopharma firm Alumis extends gains after commencing $175 mln stock offering - TradingView — Track All Markets
Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ‘Win’ — Analysts See Best-In-Class Potential - Stocktwits
Guggenheim raises Alumis stock price target to $32 on positive trial data - Investing.com UK
Why Alumis Stock Spiked Almost 100% Yesterday - TIKR.com
Alumis stock hits record high as Wall Street cheers phase 3 psoriasis 'win' — analysts see best-in-class potential - MSN
Should You Jump Into the Alumis Stock Rally Now? - Bitget
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | - GuruFocus
Sandisk, Alumis, Micron Technology, Ventyx Biosciences, And Western Digital: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Assessing Alumis (ALMS) Valuation After Positive Envudeucitinib Phase 3 Trial Success - simplywall.st
Alumis plans $175 million common stock offering By Investing.com - Investing.com Nigeria
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - Yahoo Finance
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - The Motley Fool
Alumis’ TYK2 envu in view as standout in psoriasis phase III - BioWorld MedTech
Alumis stock nearly doubles on 'truly remarkable' drug trial, plan to seek FDA approval - The Business Journals
Alumis Looks To Come From Behind In TYK2 Race - Citeline News & Insights
Why This J&J Rival Just Catapulted More Than 95% - Investor's Business Daily
Alumis Announces Proposed Public Offering of Common Stock - The Manila Times
Biotech Alumis plans $175M stock sale in new public offering - Stock Titan
Alumis (ALMS) Sees Analyst Rating Boost with New Price Target | ALMS Stock News - GuruFocus
Alumis Inc.: Is It Too Late To Buy? - StocksToTrade
Oppenheimer raises Alumis stock price target to $50 on positive trial results - Investing.com UK
Dow Jumps Over 400 Points; US Services Activity Falls In December - Benzinga
Alumis posts late-stage trial successes for TYK2 inhibitor in plaque psoriasis - FirstWord
Alumis Inc. Stock (ALMS) Opinions on Phase 3 Trial Results - Quiver Quantitative
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Alumis soars as TYK2 drug hits mark in psoriasis trials - BioPharma Dive
Alumis (NASDAQ:ALMS) Sets New 12-Month HighWhat's Next? - MarketBeat
Alumis Skin Medication Demonstrates Significant Advantages in Advanced Trials, Shares Surge - Bitget
Alumis’ TYK2 drug succeeds in key psoriasis studies, will seek FDA approval - Endpoints News
Alumis Shares Jump as Envudeucitinib Hits Phase III Endpoints in Psoriasis, NDA Planned for 2026 - MarketBeat
Baird raises Alumis stock price target to $35 on strong psoriasis trial data - Investing.com Canada
Alumis Stock Hits Record High on Psoriasis Drug Trial Results - Schaeffer's Investment Research
Alumis price target raised to $39 from $17 at Wells Fargo - TipRanks
Alumis Skin Drug Shows Clear Benefits In Late Trials, Stock Soars - Benzinga
Alumis (ALMS) Stock: Clinical Trial Results Send Shares Up 60% on Tuesday - Blockonomi
Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high - ts2.tech
Alumis posts late-stage trial win plaque psoriasis drug (ALMS) - Seeking Alpha
Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is ALMS stock rising today? - MSN
US Stocks Mixed; Nasdaq Gains Over 50 Points - Benzinga
Crypto: Alumis Inc. Explodes 113.96% – The Hidden Forces Behind This Stunning Rally! - InteractiveCrypto
Why Is ALMS Stock Rising Today? - Stocktwits
Crypto: Alumis Inc's Explosive 113.96% Surge: The Secrets Behind the Stunning Rally - InteractiveCrypto
Alumis Shares Surge After Plaque Psoriasis Drug Trials Meet Endpoints - MarketWatch
Alumis shares surge to record high as skin disease drug aces late-stage trials - marketscreener.com
Alumis stock soars after drug shows strong psoriasis results in Phase 3 By Investing.com - Investing.com South Africa
Alumis stock soars after drug shows strong psoriasis results in Phase 3 - Investing.com Australia
Alumis unveils positive phase 3 data for psoriasis drug - MSN
Alumis Inc Azioni (ALMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alumis Inc Azioni (ALMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | Director |
Dec 03 '25 |
Buy |
7.75 |
100,000 |
775,000 |
1,012,849 |
| AKKARAJU SRINIVAS | Director |
Dec 02 '25 |
Buy |
7.55 |
96,000 |
724,800 |
912,849 |
| AKKARAJU SRINIVAS | Director |
Dec 04 '25 |
Buy |
8.18 |
66,027 |
540,101 |
1,078,876 |
| AKKARAJU SRINIVAS | Director |
Dec 01 '25 |
Buy |
7.46 |
86,350 |
644,171 |
816,849 |
| AKKARAJU SRINIVAS | Director |
Nov 26 '25 |
Buy |
7.64 |
48,537 |
370,823 |
691,797 |
| AKKARAJU SRINIVAS | Director |
Nov 28 '25 |
Buy |
7.64 |
38,702 |
295,683 |
730,499 |
| Foresite Capital Management VI | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Tananbaum James B. | Director |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| Foresite Labs, LLC | 10% Owner |
Nov 21 '25 |
Buy |
7.38 |
72,212 |
532,925 |
2,614,215 |
| AKKARAJU SRINIVAS | Director |
Nov 20 '25 |
Buy |
7.20 |
125,743 |
905,350 |
643,260 |
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):